
Quarterly ResultNov 3, 2026, 04:14 PM
Alamar Biosciences Q3 Revenue $33.5M (+68% YoY); Raises 2026 Guidance
AI Summary
Alamar Biosciences announced its third quarter 2026 financial results, reporting a 68% year-over-year revenue increase to $33.5 million and raising its full-year revenue guidance. The company also announced that President Timothy "Tod" White will retire at the end of 2026 but will continue as a consultant. Key financial highlights include strong growth in instrument, consumable, and services revenue, along with an improved gross margin. Despite increased operating expenses due to investments, the company's financial performance shows significant positive momentum.
Key Highlights
- Alamar Biosciences reported Q3 2026 revenue of $33.5 million, a 68% increase year-over-year.
- Full-year 2026 revenue guidance raised to $121-$123 million, up from $116-$120 million.
- President Timothy "Tod" White to retire effective December 31, 2026, will remain as consultant.
- Instrument revenue grew 50% to $8.5 million; Consumable revenue grew 79% to $17.8 million.
- Services and other revenue grew 69% to $7.2 million.
- Gross margin improved to 61.5% from 59.7% year-over-year.
- Operating expenses increased 81% to $35.8 million due to planned investments.
- Net loss was $13.3 million for Q3 2026, compared to $8.0 million in Q3 2025.
Price Impact
More from ALMR